Urokinase plasminogen activator receptor targeting peptides

uPAR-targeting peptide conjugates with a fluorophore and hydrophilic linker enhance tumor visualization in cancer surgery by achieving high tumor-to-background ratios, addressing the limitations of current imaging techniques in real-time, high-resolution cancer-specific visualization.

JP7584492B2Active Publication Date: 2024-11-15RIGSHOSPITALET +2
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2022502488
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-16
Filing Date
2020-07-15
Publication Date
2024-11-15
Estimated Expiration
2040-07-15

AI Technical Summary

Technical Problem

Current surgical imaging techniques for cancer, particularly glioblastoma (GBM), lack the ability to provide real-time, high-resolution, and cancer-specific visualization of tumor margins due to low tumor-to-background ratios (TBR) and non-specific uptake in healthy tissue, making complete tumor resection challenging.

Method used

Development of urokinase plasminogen activator receptor (uPAR)-targeting peptide conjugates with a fluorophore and a hydrophilic linker group, enhancing binding affinity and solubility, providing optimal pharmacokinetic profiles for improved tumor visualization.

Benefits of technology

The uPAR-targeting peptide conjugates achieve high tumor-to-background ratios (TBR) and specific tumor visualization, enabling precise delineation of cancerous tissue from healthy tissue during surgery, with improved safety and reduced exposure to harmful radiation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584492000005
    Figure 0007584492000005
  • Figure 0007584492000006
    Figure 0007584492000006
  • Figure 0007584492000007
    Figure 0007584492000007
Patent Text Reader

Abstract

The present invention describes a uPAR-targeting peptide conjugate comprising a covalently linked fluorophore, a peptide that binds to uPAR, and a linker group, which can be used as a fluorescent probe in real-time optical imaging and delineation of cancer tumors or metastases during surgery.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a uPAR targeting peptide conjugate with an optimal pharmacokinetic profile intended for administration into the human or animal body.Furthermore, the uPAR targeting peptide conjugate and the composition comprising the uPAR targeting peptide conjugate are provided for use in optical imaging and for the diagnosis and / or treatment of disease. [Background technology]

[0002] Surgery remains the most common method of treating cancer diseases. The best outcome of cancer surgery is to remove all cancer cells, if possible, since the goal outcome of cancer treatment is the complete removal of the cancer tissue. To achieve this goal, a certain amount of healthy tissue around the tumor is also mercilessly removed. All removed tissue is carefully examined by microscopic examination, which allows the pathologist to determine the extent and characteristics of the spread of the disease. Therefore, delineating the margins of active tumors is a great challenge, and the location and extent of tumor spread is usually mapped preoperatively with computed tomography (CT) or magnetic resonance imaging (MRI). However, the lack of real-time imaging tools, low resolution, and in the case of CT, harmful ionization, limit these techniques by preventing continuous real-time intraoperative imaging, i.e., positron emission tomography (PET) or CT imaging, from being performed in a convenient setting while the surgery is in progress.

[0003] On the other hand, fluorescence imaging allows non-invasive in vivo visualization in real time with high temporal and spatial resolution without exposing the subject or staff in the operating room to harmful ionizing radiation. Thus, fluorescence imaging can be used to visualize organisms and tissues safely, simply, and in real time at very high resolution.

[0004] Glioblastoma (GBM) is a severe cancer disease that is essentially incurable, with a disappointing median survival of 14 months, even with aggressive multimodal treatments. Thus, multidisciplinary efforts are being made to understand the complexity of the disease and find a cure. However, progress in the past 20 years in the treatment of GBM has been modest with overall survival stagnating. Surgery remains an important treatment modality, and although surgery does not stand alone, postoperative survival rates are determined by the extent of resection. GBM has irregular borders and an infiltrative nature with tendons and single cells extending into apparently healthy tissue, making it difficult to clearly identify and completely resect while preserving healthy adjacent tissue. 5-ALA has recently been approved by the Food and Drug Administration (FDA) for GBM resection, and when metabolized to protoporphyrin IX within the tumor, it becomes fluorescent with an emission peak at 635 nm. However, because metabolites do not bind to tumor cells and are diffuse, 5-ALA does not provide clear tumor delineation, and there is low to very low evidence that 5-ALA improves glioma surgery. Methylene blue, sodium fluorescein, and indocyanine green (ICG) are FDA approved for use in humans, but they have short wavelengths in the visible spectrum (ICG in the NIR spectrum) and no cancer specificity. This limits the penetration, resolution, and contrast, expressed as tumor-to-background ratio (TBR), due to autofluorescence, tissue absorbance, scattering, photobleaching, and nonspecific uptake in healthy tissue. Therefore, new surgical imaging for effective GBM delineation is highly needed.

[0005] Targeted molecular fluorescence imaging is such a tool. By combining high-affinity targeting molecules with fluorescent dyes, cancer tissues can be specifically targeted and visualized in real time with high TBR, continuously guiding and assisting surgeons to distinguish cancer tissues from healthy tissues during surgery.

[0006] Urokinase-type plasminogen activator receptor (uPAR) is a well-known cancer target that is highly expressed in GBM and several other cancers, including but not limited to breast cancer, head and neck squamous cell carcinoma, renal cell carcinoma, and lung cancer. This receptor is associated with invasion and metastasis, one of the hallmarks of cancer, and its expression level correlates with cancer aggressiveness and poor survival prognosis. In addition, the receptor is generally highly expressed at the invasion front, including the activated tumor stromal microenvironment with chronic inflammation, making it an attractive target that allows precise visualization of the margins and delineation of the tumor. For example, WO 2016 / 041558 discloses a fluorescently labeled peptide-based probe that binds to uPAR. However, there is still room for improvement and improved methods for cancer resection are needed.

[0007] One object of the present invention is to provide improved receptor-targeting conjugates for imaging applications and / or administration prior to surgery in cancer therapy. Summary of the Invention

[0008] The above-mentioned objectives are 1. A urokinase plasminogen activator receptor (uPAR) targeting peptide conjugate comprising: Fluorophores, Peptides that bind to uPAR, and a linker group covalently linking the fluorophore, the peptide that binds to the uPAR, and the linker group; A urokinase plasminogen activator receptor (uPAR) targeting peptide conjugate, wherein the linker group comprises an oligoethylene glycol or other short oligomer, such as an oligo-glycerol, an oligo-lactic acid or a carbohydrate, optionally covalently linked to at least one amino acid. This is achieved by: The linker group provides solubilizing properties to the uPAR targeting peptide conjugate and enhances its binding properties with respect to the uPAR receptor.

[0009] In connection with the above, it should be emphasized that the probes shown in WO 2016 / 041558 do not provide optimal pharmacokinetic profiles or target affinity due to low receptor binding and slow plasma clearance, which impairs optimal and specific contrast in recorded imaging. Although TBR values ​​for various alternatives are disclosed in WO 2016 / 041558, these are both within and outside the range of levels provided for the uPAR-targeting peptide conjugates according to the present invention. In summary, the receptor-targeting conjugates according to the present invention represent novel probes that provide optimal pharmacokinetic profiles for certain administration types and indications. [Brief description of the drawings]

[0010] [Figure 1] FIG. 1 shows the molecular structure of the uPAR-targeting peptide conjugate IRDye800CW-AE344. [Diagram 2] FIG. 2 shows surface plasmon resonance analysis of the affinity of IRDye800CW-AE344 for uPAR, where the top line (1) represents IRDye800CW-AE344:uPARwt and the bottom line (2) represents AE105:uPARwt. [Diagram 3] Figure 3 shows the spectral analysis of the demonstrated absorption peak at 777 nm (solid line), excitation peak at 784 nm (dotted line), and emission peak at 794 nm (dashed line) of the probe IRDye800CW-AE344, resulting in a Stokes shift of 10 nm. [Figure 4] Figure 4 shows the photostability of IRDye800CW-AE344 after successive laser exposure. [Diagram 5] Figure 5 shows the in vivo imaging specificity of IRDye800CW-AE344 in orthotopic GBM. The top panel shows an intact brain (NIR image exposure time 500 ms) and the bottom panel shows a cross-sectional brain (NIR image exposure time 333 ms) (animal id029, 6 nmol, 3 hours). [Figure 6]Figure 6 shows brain histology with H&E staining, NIR microscopy, H&E and NIR together, and immunohistochemical staining for uPAR. Arrows indicate small leptomeningeal metastases at the base of the brain, visible in both H&E staining and NIR microscopy (12 nmol IRDye800CW-AE344, 24 hours). [Figure 7] Figure 7 shows dynamic NIR imaging of GBM ex vivo on cross-sectioned brain. The arrow in the picture indicates the highest TBR (max) for a given dose of IRDye800CW-AE344 (all data based on images with 333 ms exposure time). [Figure 8] FIG. 8 shows the tumor-to-background ratios for various doses of IRDye800CW-AE344, with lines representing doses of 1 mmol (●), 3 nmol (■), 6 nmol (▲) and 12 nmol (▼), respectively. [Figure 9] FIG. 9 shows the mean fluorescence intensity (MFI) of the tumors for different doses of IRDye800CW-AE344, with the different bars representing doses of 1 nmol, 3 nmol, 6 nmol, and 12 nmol, respectively. [Figure 10] FIG. 10 shows tumor and background mean fluorescence intensity at 6 nmol IRDye800CW-AE344 compared to TBR, where light grey (left) bars represent tumor, dark grey (right) bars represent background, and line represents TBR. [Figure 11] FIG. 11 shows NIR images of cross-sectional brains 1 hour after injection of (from left to right) 3 nmol IRDye800CW-AE344 (active), 3 nM IRDye800CW-AE344 + 600 nmol AE120 (blocking) and 3 nM IRDye800CW-AE354 (mutated). [Figure 12] Figure 12 shows normalized TBR (ref: activity probe). Black bars represent IRDye800CW-AE344 (active), light grey bars represent AE120 (blocked) and dark grey bars represent IRDye800CW-AE354 (mutated). [Figure 13]Figure 13 shows images of organs depicting the fluorescence intensity and biodistribution of 3 nmol IRDye800CW-AE344 1 hour after injection (exposure time: 333 ms). The arrow in the small intestine indicates the proximal end. The kidney was oversaturated and therefore outside the range of the color correction bar. [Figure 14] Figure 14 shows quantification of the fluorescent signal for IRDye800CW-AE344. The left y-axis represents the mean fluorescence intensity. The right y-axis represents the relative biodistribution. Additionally, the black bars represent the mean signal intensity (au) and the grey bars represent the relative biodistribution (data is normalized to the skin for highest uptake). [Figure 15] FIG. 15 shows images (white light, NIR, and both white light and NIR). [Figure 16A] FIG. 16A shows an NIR image of a cross-sectional brain 1 hour after injection. [Figure 16B] FIG. 16B shows the mean intensity of the tumor and background. [Figure 16C] FIG. 16C shows the corresponding normalized TRB values. [Figure 17] FIG. 17 shows the biodistribution and acute toxicity with all data at 1 hour after injection. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] Particular embodiments of the present invention Several specific embodiments of the present invention are presented and further described below.

[0012] According to one embodiment of the present invention, the linker group comprises an oligoethylene glycol or other short oligomers, such as oligo-glycerol, oligo-lactic acid or carbohydrates, optionally covalently linked to at least one amino acid. In one embodiment of the present invention, the linker group comprises an oligoethylene glycol covalently linked to at least one amino acid, which may be covalently linked to another amino acid forming a peptide bond, thus forming an oligopeptide. Thus, in one embodiment of the present invention, the linker group comprises an oligoethylene glycol covalently linked to at least one oligopeptide. Thus, the linker group may be a hydrophilic linker group. Furthermore, the at least one amino acid is selected from proteinogenic and non-proteinogenic amino acids, including natural and synthetic amino acids. In this context, it may be further mentioned that natural amino acids may include C-alpha alkylated amino acids, such as aminoisobutyric acid (Aib), N-alkylated amino acids, such as sarcosine, and naturally occurring beta-amino acids, such as beta-alanine. Additionally, synthetic amino acids may include amino acids with non-proteinaceous side chains, such as cyclohexylalanine, gamma-amino acids, and dipeptide mimetics. The term dipeptide mimetics may be interpreted as organic molecules that mimic dipeptides by presenting two amino acid side chains, for example by reducing the amide bond linking two residues together. Amino acids with non-proteinaceous side chains may also include amino acids with side chains that have restricted movement in the CHI space. The term restricted movement in the CHI space may be interpreted as limited flexibility in the rotation of the side chain group. Oligopeptides may consist of up to 50 amino acids and may include dipeptides, tripeptides, tetrapeptides, and pentapeptides, and may further be composed of proteinaceous and non-proteinaceous amino acids.

[0013] According to one specific embodiment of the invention, the linker group is -Glu-Glu-NH-CH2-CH2-O-CH2-CH2-O-CH2-CO-NH-CH2-CH2-O-CH2-CH2-O-CH2-CO-. When the term O2Oc is used throughout this application, it means the chemical moiety -NH-CH2-CH2-O-CH2-CH2-O-CH2-CO-. Thus, O2Oc-O2Oc means -NH-CH2-CH2-O-CH2-CH2-O-CH2-CO-NH-CH2-CH2-O-CH2-CH2-O-CH2-CO-. Furthermore, the invention is not limited to ethylene glycol units being linked by amide bonds, in fact, each ethylene unit may be linked by either an ether or amide or essentially any other covalent bond. The ethylene glycol chain can have various lengths, i.e., the number of repeating units can range from n=1 to 10, where n is -(CH2-CH2-O) n - is the number of repeat units in the linker corresponding to. Furthermore, the amino acids in the linker are not limited to glutamic acid (Glu), but may include other combinations including amino acids with acidic side chains, i.e., aspartic acid, such as Asp-Asp, Glu-Asp, or Asp-Glu. Furthermore, other hydrophilic amino acid combinations may be used, i.e., combinations of serine (Ser), threonine (Thr), histidine (His), or lysine (Lys).

[0014] According to another embodiment of the present invention, the fluorophore can be a near infrared I (NIR-I) fluorophore or a near infrared II (NIR-II) fluorophore. The fluorophore can be selected from the group consisting of ICG, methylene blue, 5-ALA, protoporphyrin IX, IRDye800CW, ZW800-1, Cy5, Cy7, Cy5.5, Cy7.5, IRDye700DX, Alexa fluor488, fluorescein isothiocyanate, Flab7, CH1055, Q1, Q4, H1, IR-FEP, IR-BBEP, IR-E1, IR-FGP, IR-FTAP.

[0015] Furthermore, according to another specific embodiment of the present invention, the fluorophore may be a NIR-I fluorophore selected from the group consisting of ICG, methylene blue, 5-ALA, protoporphyrin IX, IRDye800CW, ZW800-1, Cy5, Cy7, Cy5.5, Cy7.5, IRDye700DX, Alexa fluor 488, fluorescein isothiocyanate. According to another specific embodiment of the present invention, the fluorophore may be a NIR-II fluorophore selected from the group consisting of Flav7, CH1055, Q1, Q4, H1, IR-FEP, IR-BBEP, IR-E1, IR-FGP, IR-FTAP. According to one specific embodiment of the present invention, the fluorophore is IRDye800CW. Additionally, the fluorophores of the present invention may have NIR light absorption in the range of 700-1200 nm for NIR-I fluorophores, 700-950 nm, or 1000-1200 nm for NIR-II fluorophores. Similarly, the fluorophores may have NIR emission in the range of 700-1200 nm for NIR-I fluorophores, 700-950 nm, or 1000-1200 nm for NIR-II fluorophores. NIR fluorophores, when used for fluorescence imaging, offer the advantage of providing a window for generating deep tissue images.

[0016] In another embodiment of the invention, the receptor-binding peptide may be selected from the group consisting of: -Asp-Cha-Phe-ser-arg-Tyr-Leu-Trp-Ser; and -Asp-Cha-Phe-ser-arg-Tyr-Leu-Trp-Ser-NH2.

[0017] Furthermore, the covalent bond of the present invention may be selected from the group consisting of amides, carbamates, thioureas, esters, ethers, amines, triazoles, or any other covalent bond commonly used to attach chemical moieties by solid phase synthesis.

[0018] According to one specific embodiment of the invention, the uPAR targeting peptide conjugate is of the following formula: [ka]

[0019] According to another specific embodiment of the invention, the uPAR targeting peptide conjugate corresponds to IRDye800CW-Glu-Glu-O2Oc-O2Oc-Asp-Cha-Phe-D-Ser-D-Arg-Tyr-Leu-Trp-Ser-OH, wherein Cha can be interpreted as β-cyclohexyl-L-alanine.

[0020] In another embodiment of the invention, the uPAR targeting peptide conjugate has a uPAR binding affinity of less than 100 nM, preferably less than 50 nM, preferably less than 25 nM.

[0021] As alluded to above, the uPAR targeting peptide conjugates according to the invention exhibit optimal pharmacokinetic profiles for specific administration types and indications.

[0022] In terms of pharmacokinetics, according to one embodiment of the present invention, the uPAR targeting peptide conjugate has -Administered systemically into the human or animal body; - effecting receptor binding within at least 4,500 minutes, preferably within 1,200 minutes, more preferably within 600 minutes, even more preferably within 300 minutes; - having a plasma half-life of up to 4,500 minutes, preferably 1,200 minutes, more preferably 600 minutes, even more preferably 300 minutes, measured as the plasma half-life, which is the time it takes for the concentration in plasma to decrease by 50% after removal from the plasma to visualize the conjugate bound to the receptor; - Receptor binding is sustained for at least 30 minutes; The receptor binding affinity, the time taken to reach the desired receptor binding, the persistence of the receptor binding and the plasma half-life translate into a TBR (tumor to background ratio) of at least 1.5, which level is reached within 4,500 minutes, preferably within 1,200 minutes, more preferably within 600 minutes, and even more preferably within 300 minutes after administration to the human or animal body, and which remains above 1.5 for at least 30 minutes after this level is achieved.

[0023] According to yet another embodiment, the rate at which the protein (P)-ligand (L) complex is formed may be defined as follows:

number

[0024] According to yet another embodiment, the receptor affinity is determined by IC, which is a measure of ligand / receptor binding affinity. 50 and is less than 3000 nM.

[0025] Moreover, according to one specific embodiment, receptor binding affinity is achieved within a time period of 30 minutes as measured in vitro.

[0026] Moreover, according to yet another embodiment, receptor binding lasts for at least 120 minutes, preferably at least 300 minutes, after administration into the human or animal body as measured using a TBR of greater than 1.5.

[0027] According to another aspect, the present invention relates to a uPAR targeting peptide conjugate for use in the treatment of disease.

[0028] According to a further aspect, the present invention relates to a uPAR targeting peptide conjugate for use in optical imaging or fluorescence imaging (FLI) of disease. Fluorescence imaging allows non-invasive in vivo visualization, as well as in vitro visualization, in real time with high temporal and spatial resolution, without exposing the subject to harmful ionizing radiation. Thus, fluorescence imaging can be used for safe and long repeated visualization of living organisms and tissues. Thus, the uPAR targeting peptide conjugate of the present invention can be administered to a subject at a dose of 0.1 to 1000 mg per person.

[0029] In yet a further aspect, the present invention relates to a pharmaceutical composition comprising uPAR targeting peptide conjugate together with at least one pharma- ceutically acceptable carrier or excipient.The present invention also relates to a pharmaceutical composition of the present invention for use in treating disease.Furthermore, the present invention relates to a pharmaceutical composition for use in detecting and / or quantifying disease.Furthermore, the present invention relates to a pharmaceutical composition for use in diagnosing disease.The present invention also relates to a pharmaceutical composition for use in optical or fluorescent imaging (FLI) of disease.

[0030] In one embodiment of the present invention, the disease can be selected from the group consisting of cancer and inflammatory disease.In addition, because uPAR is a well-known cancer target that is highly expressed in GBM and some other cancers, the cancer targeted by the present invention can be GBM, including other brain cancers (including central and peripheral nervous system), breast cancer, head and neck squamous cell carcinoma and other head and neck cancers (for example, lip cancer, oral cavity cancer, laryngeal cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer), renal cell carcinoma, lung cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, thyroid cancer, bladder cancer, esophageal cancer, pancreatic cancer, kidney cancer, uterine body cancer, cervical cancer, melanoma, ovarian cancer, gallbladder cancer, multiple myeloma, testicular cancer, vulvar cancer, salivary gland cancer, mesothelioma, penile cancer, Kaposi's sarcoma, vaginal cancer, neuroendocrine tumor and neuroendocrine cancer.

[0031] In one embodiment of the invention, the cancer may be selected from the group consisting of glioma, glioblastoma or other brain tumors, pancreatic cancer, head and neck cancer, breast cancer, lung cancer, colorectal cancer, esophageal cancer, gastric cancer, liver cancer, neuroendocrine tumors, neuroendocrine cancer, and prostate cancer.

[0032] In one embodiment of the present invention, cancer is selected from the group consisting of glioma, glioblastoma, pancreatic cancer, head and neck cancer, colorectal cancer, lung cancer and breast cancer.Furthermore, in one specific embodiment of the present invention, cancer is glioma or glioblastoma.In another specific embodiment of the present invention, cancer is pancreatic cancer.In yet another specific embodiment of the present invention, cancer is breast cancer.

[0033] Furthermore, selectivity for cancer tissue is also of interest in the context of the present invention. According to one specific embodiment of the present invention, the receptor-targeting conjugate has a selectivity for cancer tissue of at least 60%, preferably more than 70%, more preferably more than 80%, and most preferably more than 90%. Thus, the conjugate product is preferably characterized as having a selectivity for cancer tissue of at least 60%, or 70%, or 80%, or 90%. Due to some or all of its properties. Selectivity identifies the relative number of tissue samples that the surgeon removes thinking they are cancerous based on their light intensity / contrast, and that are subsequently confirmed to be cancerous. An example would be removing 10 tissue samples that the surgeon thinks are cancerous, and 7 of them are histologically confirmed to be cancerous, indicating a selectivity of 7 / 10-70%. If 100% of the tissue samples that the surgeon removed thinking they were cancerous are proven to be cancerous, then the selectivity is 100%. If only half of the tissue samples removed by the surgeon are cancerous and the other half are normal tissue, then the selectivity is 50%.

[0034] In another embodiment of the invention, the inflammatory disease is selected from the group consisting of arthritis and atherosclerosis.

[0035] In a further aspect, a pharmaceutical composition is provided for use in delineating cancer tumors or metastases. In yet a further aspect, a pharmaceutical composition is provided for use in fluorescence-guided tumor resection or metastasectomy. In this regard, the pharmaceutical composition can be administered intravenously, locally or topically. The concentration of the uPAR targeting peptide conjugate is 0.1-1000mg per dosage unit. Typically, the concentration of a uPAR targeting peptide conjugate according to the present invention may be in the range of 0.001-1000 mg per dosage unit, 0.01-1000 mg per dosage unit, 0.1-1000 mg per dosage unit, 0.0001-500 mg per dosage unit, 0.001-500 mg per dosage unit, 0.01-500 mg per dosage unit, 0.1-500 mg per dosage unit, 0.0001-100 mg per dosage unit, 0.001-100 mg per dosage unit, 0.01-100 mg per dosage unit, or 0.1-100 mg per dosage unit.

[0036] In a further aspect, (i) administering to a target tissue a urokinase plasminogen activator receptor (uPAR) targeting peptide conjugate comprising a fluorophore, a receptor-binding peptide, and a linker group covalently attaching said fluorophore to said receptor-binding peptide, wherein said receptor-binding peptide is bound to uPAR; (ii) allowing time for the uPAR targeting peptide conjugate to accumulate in the target tissue and establishing a tumor / target tissue to background ratio; (iii) irradiating the target tissue with near-infrared light of a wavelength that can be absorbed by the fluorophore; (iv) detecting fluorescence emitted by the fluorophore and forming an optical image of the target tissue. An optical imaging method is provided, comprising:

[0037] As used herein, the term "tissue" refers to isolated in vitro and ex vivo cells and / or tissues as well as in vivo tissues. In one embodiment of the present invention, the optical imaging method comprises (i) administering a uPAR targeting peptide conjugate to a target tissue in vivo. In another embodiment of the present invention, the optical imaging method comprises (i) administering a uPAR targeting peptide conjugate to a target tissue in vitro. The optical imaging method according to the present invention provides a time for the uPAR targeting peptide conjugate to accumulate in the target tissue to obtain a sufficiently high TBR, which is up to 360 minutes, 180 minutes, 120 minutes, 90 minutes, 60 minutes, 45 minutes, 30 minutes, 15 minutes, 10 minutes or 5 minutes after administration. In a particular embodiment, the accumulation time of the uPAR targeting peptide conjugate in the target tissue is up to 60 minutes, preferably 45 minutes, preferably 30 minutes, preferably 15 minutes, preferably 10 minutes or preferably 5 minutes after administration. Furthermore, the tumor / target tissue to background ratio is at least 2.

[0038] In one embodiment of the method of the present invention, the fluorophore has NIR light absorption in the range of 700-800 nm. Furthermore, the fluorophore has NIR emission in the range of 750-900 nm. Thus, the uPAR targeting peptide conjugates are successfully visualized in cancers within the NIR spectrum, with improved brightness and photostability. Furthermore, the uPAR targeting peptide conjugates of the present invention have improved TBR, pharmacokinetics, signal strength, and increased water solubility.

[0039] In one embodiment of the present invention, the optical imaging method is performed in vivo. The optical imaging method may also be performed in vitro.

[0040] In another aspect, (i) administering the uPAR targeting peptide conjugate of the present invention to a target tissue; (ii) allowing time for the uPAR targeting peptide conjugate to accumulate in the target tissue for a set time period within the range of 1 to 120 minutes after administration; (iii) irradiating the target tissue with near infrared light at a wavelength that can be absorbed by the fluorophore of the uPAR targeting peptide conjugate; (iv) detecting the fluorescence emitted by the fluorophore of the uPAR targeting peptide conjugate; and (v) forming an optical image of said target tissue, or quantifying disease, or forming an optical image and quantifying disease. A method for detecting a disease is provided, comprising:

[0041] In yet another embodiment, the use of the uPAR targeting peptide conjugate or pharmaceutical composition according to the present invention is provided for optical imaging of cancer.There is also an embodiment of the present invention that provides the use of the uPAR targeting peptide conjugate or pharmaceutical composition for fluorescence-guided tumor resection or metastasectomy.

[0042] In one embodiment of the present invention, the method for detecting disease is carried out in vivo. The method for detecting disease can also be carried out in vitro. In one embodiment of the present invention, the method for detecting disease comprises (i) administering uPAR targeting peptide conjugate to target tissue in vivo. In another embodiment of the present invention, the method for detecting disease comprises (i) administering uPAR targeting peptide conjugate to target tissue in vitro.

[0043] A further aspect also relates to a unit dose of the pharmaceutical composition of the invention, optionally a unit dose of at least one pharmacologically active substance, optionally, a unit dose of an adjuvant, - optionally at least one pharma- ceutically acceptable carrier or excipient in a unit dose; - a means for separating the unit doses from one another prior to administration, and -means for administering the unit dose The present invention relates to a kit of parts for preparing a unit dose of a uPAR targeting peptide conjugate formulation, comprising:

[0044] In one embodiment, the kit of parts according to the invention provides a unit dose of the pharmaceutical composition in the range of 0.0001-1000 mg. Typically, the unit dose of the pharmaceutical composition according to the invention may alternatively be in the range of 0.001-1000 mg, 0.01-1000 mg, 0.1-1000 mg, 0.0001-500 mg, 0.001-500 mg, 0.01-500 mg, 0.1-500 mg, 0.0001-100 mg, 0.001-100 mg, 0.01-100 mg, or 0.1-100 mg. Furthermore, the unit dose may be in the range of 0.1-10.0 mL total volume, preferably in the range of 0.1-5.0 mL, preferably in the range of 0.5-5.0 mL, preferably in the range of 0.5-1.0 mL.

[0045] Detailed Description of the Figures and Examples Although individual features may be included in various embodiments, these may possibly be combined in other ways, and inclusion in various embodiments does not imply that a combination of several features is not feasible. Moreover, reference in the singular does not exclude a plurality. In the context of the present invention, the terms "a" and "an" do not exclude a plurality.

[0046] The term "conjugate" means two or more molecules, such as a peptide and a linker and a fluorophore, covalently joined together.

[0047] Key features of an optimal fluorescent probe for surgical guidance include high sensitivity, high specificity, a high TBR achieved immediately after injection (1 h), low dose and nevertheless high fluorescent signal, easy synthesis with high yield, and it must be well tolerated (non-toxic).

[0048] SPR experiments 100 fmol / mm 2Human purified prouPA was assayed by injecting 12.5 μg / ml protein dissolved in 10 mM sodium acetate (pH 5.0) to target a surface density of >5000 resonance units (RU), corresponding to S356A -covalent immobilization of uPAR was achieved. After coupling, the sensor chip was deactivated with 1 M ethanolamine. Binding of human purified uPAR as analyte was measured at 4 nM to 0.25 nM at 20 °C using 10 mM HEPES, 150 mM NaCl, 3 mM EDTA (pH 7.4) with 0.05% (v / v) surfactant P20 as running buffer at a flow rate of 50 μl / min. Between cycles, the sensor chip was regenerated by two successive 10 μl injections of 0.1 M acetic acid / HCl (pH 2.5) in 0.5 M NaCl. Inhibition of 3-fold dilutions of the compound in question was measured for 4 nM uPAR under identical running conditions. All experiments were performed on a Biacore T200 instrument.

[0049] result For each inhibitor peptide inhibition profile of uPAR binding to immobilized uPA, a preceding standard curve was generated and all calculations were based on that standard curve. The results are summarized in Table 1. [Table 1]

[0050] From Table 1, it is clear that a second generation uPAR targeting peptide has been generated that is unexpectedly better than the original ICG-EE-AE105. In contrast to the ICG derivative, both the IRDye800CW mutant of AE105 (AE353) target wtuPAR with high affinity and show low affinity to the restricted uPAR mutant (negative control). By expanding the hydrophilic linker region, a product with much better solubility properties is obtained, maintaining the original high affinity of the parent peptide (AE105) despite tethering a large reporter group at its N-terminus (IRDye800CW).

[0051] Biochemical and optical properties The present invention describes the synthesis of a uPAR-targeting fluorescent probe based on the uPAR-targeting peptide conjugate IRDye800CW-AE344, whose molecular structure is shown in Figure 1. The binding properties to uPAR are preserved and IC50 was determined for competition for binding of the natural ligand urokinase-type plasminogen activator. 50 = 20 nM ± 1.1 nM (SD) was obtained (Figure 2).

[0052] The vis / NIR spectral characteristics are abs,max = 777 nm (Figure 3) and λ excitation,max The fluorescence emission spectrum showed a slightly right-shifted excitation profile with an excitation peak at λ = 784 nm. emission,max The compound showed a peak emission at = 794 nm, resulting in a Stokes shift of 10 nm. Photostability demonstrated that 84% of the fluorescence intensity was preserved after 1 h of continuous laser exposure and 62% after 2 h (Figure 4).

[0053] In vivo cancer imaging specificity In one embodiment of the present invention, the fluorescent probe IRDye800CW-AE344 was subjected to in vivo cancer imaging. With visible light, orthotopic GBM was not visualized through intact brains, but was clearly visualized with NIR imaging (Figure 5). Furthermore, in sectioned brains, the tumor extent appeared clearly distinct from healthy tissue, allowing differentiation of tumor tissue from healthy brain tissue. Histological evaluation revealed colocalization of tumor extent with H&E staining, NIR microscopy, and uPAR staining immunohistochemistry (Figure 6), demonstrating that the optical probe of the present invention precisely targets biomarkers / tumors with high sensitivity (all tumors are fluorescent) and high specificity (all fluorescent signals are tumor tissue).

[0054] For fluorescence-guided surgery (FGS), surgeons rely on clear discrimination (signal intensity) and differentiation (TBR). A high dose of 12 nmol revealed a similarly high TBR of 6.7, but came at the risk of both delaying the peak time by 15 hours and reducing tumor MFI by 58% at 6 nmol. Thus, an ideal probe and optimal dose should result in both high intensity and high TBR.

[0055] Compared to the prior art, the uPAR targeting peptide conjugates have improved water solubility, higher signal intensity and increased TBR. Thus, the fluorescent probe of the present invention safely visualizes GBM with a high TBR of over 4.5 from 1 to 12 hours after injection of 6 nmol, which allows for flexible use and fully complies with standard workflows in surgical departments, for example, the probe can be injected immediately before surgery, as soon as venous access is established in preparation for surgery / anesthesia. A useful time frame is reached when surgery is initiated and sustained throughout even a long surgery. The highest TBR, 7.0, was observed 3 hours after injection of 6 nmol, showing high absolute signal intensity. Moreover, the long incubation times intended to give the fluorescent probe time to leave the circulation and localize within the tumor are highly impractical and do not fit into established clinical workflows, requiring patients to be seen for additional consultations several days before surgery. It is also not uncommon for surgery to be postponed or canceled at the last minute.

[0056] Dynamic Imaging In another example, dynamic imaging of orthotopic GBM in cross-section revealed clear tumor visualization at all four doses (1, 3, 6 and 12 nmol). The highest TBR (7.0) was observed 3 hours after injection for the 6 nmol dose (Figure 7). The other doses tested showed maximum TBRs of 4.4 (1 nmol), 6.6 (3 nmol) and 6.7 (12 nmol) at 0.5, 1 and 15 hours, respectively (Figure 8). The corresponding tumor mean fluorescence intensity (MFI) was 29, 77, 82 and 48 (au) for the 1, 3, 6 and 12 nmol doses (exposure time of 333 ms), respectively. Thus, a correlation between fluorescence intensity and dose was observed with increasing intensity (both tumor and background) with increasing dose (Figure 9). The MFI in both tumor and background was highest at the time of injection and continuously decreased over time. Interestingly, at 6 nmol, the TBR first increased from 4.7 at 1 h to 7.0 at 3 h, followed by a decrease to 6.1 and 4.5 at 6 and 12 h, respectively. At the same time, the tumor MFI continuously decreased from 108 (au) at 1 h to 82 (au) at 3 h, corresponding to a 24% decrease (Figure 10). The background MFI at the same time point decreased from 24 (au) to 11 (au), corresponding to a 54% decrease, thus resulting in an increase in the TBR indicating a higher background clearance rate compared to the tumor clearance rate from 1 h to 3 h.

[0057] In vivo binding specificity Competitive blocking and administration of a control ligand (IRDye800CW-AE354; a non-binding scrambled peptide) in animals with orthotopic GBM resulted in lower signal intensity compared to the active probe (Figure 11). Normalized TBR values ​​for groups receiving the active, blocking or scrambled probe were 1.00 (baseline), 0.70 (p=0.006) and 0.52 (p=0.001), respectively (Figure 12).

[0058] Pharmacokinetics and Toxicity At 1 h, the kidney showed the highest MFI at 1,236 (au), followed by the lung, skin, and liver at 101 (au), 99 (au), and 88 (au), respectively. In comparison, the tumor showed a signal of 65 (au) and the brain showed a signal of 19 (au) (Figure 14). Biodistribution showed accumulation primarily in the skin and kidney, with normalized uptake in major organs as follows: skin = 100 (reference), kidney = 38.8, lung = 4.2, heart = 0.4, spleen = 0.4, liver = 12.2, pancreas = 3.4, colon = 4.0, small intestine = 11.2, ventricle 0.9, brain = 0.7, tumor = 0.1. Signal in the small intestine was restricted to the proximal intestine / intestinal contents, with only moderate signal seen in the distal portion (also shown in Figures 13 and 17A).

[0059] In Figure 17, biodistribution and acute toxicity are shown. All data are 1 hour after injection. As in Figure 13, in Figure 17A, images of organs are shown (exposure time: 333 ms) showing the fluorescence intensity and biodistribution of 3 nmol IRDye800CW-AE344. The arrows in the small intestine indicate the proximal end. The kidneys are saturated and therefore out of range in the color calibration bar. In Figure 17B, liver histology (H&E staining) is shown. Additionally, in Figure 17C, kidney tissue is shown (H&E staining). Histologically, liver tissue was normal with lobular morphology without inflammation, fibrosis, cholestasis or deposits. Renal tissue was normal, with glomeruli and tubules preserved and no atrophy, inflammation or fibrosis.

[0060] Quantification of the fluorescent signal (data normalized to skin) is shown in 17D. In Figure 17E, plasma stability quantified as area under the curve (AUC) in HPLC normalized to 0 hours is shown. The probe was stable within the relevant time window with normalized area under the curve (AUC) values ​​of 73% and 67% of the intact probe after 6 and 12 hours, respectively, in mouse plasma, and 61% and 43% of the intact probe after 6 and 12 hours, respectively, in human plasma.

[0061] plasma stability 1,600ul of human and mouse plasma were incubated separately with 2.4nmol of IRDye800-AE344 in 10ul of PBS at 37°C in the dark. 200ul samples were collected at 0, 0.5, 1, 2, 3, 6, 12 and 24 hours. Plasma proteins were precipitated by adding 200ul of acetonitrile and samples were centrifuged at 10,000G for 10 minutes. Supernatants were collected for analysis. Supernatants from time 0 from both human and mouse serum were analyzed to confirm the retention time of intact IRDye800CW-AE344 in HPLC-MS on an RSLC Dionex Ultimate 3000 (Thermo) instrument coupled to a QTOF Impact HD. The column was an Aeris widepore 3.6 μm C4 column (150 × 4.6 mm, Phenomenex) and the solvent system was Solvent A: water containing 0.1% formic acid; Solvent B: acetonitrile with 0.1% formic acid. Method: 5% solvent B from 0 to 1 min, 5% to 50% solvent B from 1 to 18 min, flow rate 1 mL / min. This showed that the intact molecule eluted after 14 min. The method, column and solvent were then transferred to another Dionex Ultimate 3000 (Thermo) with a 3100-FLD fluorescence detector using 774 nm as the excitation wavelength and measuring emission at 798 nm. All samples were then run using the above settings and the AUC of the 14 min peak was used to calculate the degradation at 0 h for both mouse and human plasma relative to this.

[0062] Fluorescence-guided resection Preoperatively, the tumor was visible on WL (white light) and NIR images (Figure 15, top panel). The surgeon performed the resection only with WL assistance until all tumor tissue was deemed to have been removed. The operating table was then evaluated by FLI, and the NIR signal revealed residual tumor tissue that had not been identified and removed in the WL (Figure 15, middle panel). With NIR assistance, the surgeon identified additional tumor tissue and resected it until no or almost no NIR signal was visible, indicating that the tumor was completely resected (Figure 15, bottom panel). A video of the fluorescence-guided surgery is also available in the online supplementary material.

[0063] As can be seen from the above, FIG. 15 shows fluorescence-guided surgery (6 nmol IRDye800CW-AE344 at 3 hours) performed with the EleVision™ IR system. Top panel: Images were acquired before surgery. Interrupted panel: Pictures were acquired after surgery with white light, clearly visualizing the remaining tumor tissue. This signal is stronger compared to the top panel, due to the fact that the remaining tumor is now more exposed. Bottom panel: Images were acquired at the end of the fluorescence-guided surgery, showing that the fluorescent tissue has been completely removed, and the tumor has been completely resected.

[0064] In vivo binding specificity Competitive blocking of IRDye800CW-AE344 binding with AE120 (dimeric version of AE105) and administration of the inactive non-targeted version of IRDye800CW-AE354 in orthotopic GBM showed lower signal intensity compared to the active probe (see Figures 16A and 16B). In Figure 16A, NIR images of cross-sectional brains are shown 1 hour after injection of (from left to right): 3 nmol IRDye800CW-AE344 (active), 3 nmol IRDye800CW-AE344 + 1.7 mg AE120 (dimeric version of AE105) (blocking), and 3 nmol IRDye800CW-AE354 (binding inactive). Images are contrast enhanced as are scale bars representing true values. In Figure 16B, the mean fluorescence intensity of the tumor and background is shown.

[0065] The normalized TBR values ​​corresponding to groups receiving the active, blocking or inactive probes were 6.6, 4.6 (p=0.012) and 3.4 (p=0.0025), respectively (see FIG. 16C).

[0066] experiment Biochemistry, optical properties and binding specificity A tumor-targeting NIR probe was developed by conjugating the IRDye® 800CW fluorophore (LI-COR) with the small uPAR-targeting peptide AE105.

[0067] The peptides were prepared by Fmoc solid-phase peptide synthesis using FmocSer(t-Bu)TentaGel S PHB 0.25 mmol / g resin on an automated peptide synthesizer (Biotage® Syro Wave). 5 mg of IRDye®800CW was then conjugated to the peptides by HATU / HOAT coupling.

[0068] The crude probe was purified by a three-step process on RP-HPLC (Dionex Ultimate 3000 system equipped with a fraction collector). Step 1: Preparative C18 column (Phenomenex Gemini, 110 Å 5 μm C18 particles, 21 × 100 mm), Solvent A: water + 0.1% TFA, Solvent B: acetonitrile + 0.1% TFA. Gradient elution at a flow rate of 15 mL / min (0-5 min: 5%; 5%-60% 5-32 min). Fractions containing the fluorescent probe were lyophilized. Step 2: Preparative C4 column (Phenomenex Jupiter, 300 Å 5 μm C18 particles, 21 × 100 mm), Solvent A: water + 0.1% TFA, Solvent B: methanol + 0.1% TFA. Gradient elution at a flow rate of 15 mL / min (0-5 min: 5%; 5%-60% 5-32 min). The fractions containing the fluorescent probe were lyophilized. Step 3: Preparative C18 column (Phenomenex Gemini, 110 Å 5 μm C18 particles, 21 × 100 mm), Solvent A: water + 0.1% TFA, Solvent B: acetonitrile + 0.1% TFA. Gradient elution at a flow rate of 15 mL / min (0-5 min: 5%-30; 30%-40% 5-40 min). The fractions containing the fluorescent probe were lyophilized. The product was verified by mass spectrometry and purity was assessed by two-stage analytical RP-HPLC.

[0069] Fluorophore excitation and emission profiles were obtained using a PTI QuantaMaster 400 (Horiba, Ltd., Japan). A xenon arc lamp was used as the excitation source, and λ emission Measure the excitation profile at λ = 850 nm, excitation Emission profiles were measured at 740 nm. Absorption was measured with a Cary 300 UV-Vis (Agilent, Santa Clara, CA, USA).

[0070] Photostability was assessed by a two-fold dilution series with four samples from 0.23 to 1.8 nM IRDye800-AE344 in 100 μL of phosphate-buffered saline (PBS) in a black 96-well plate. The wells were placed in a dark box with a Fluobeam attached on top at a distance of 23 cm from the well plate. Image acquisition was performed at 0 min, 10 min, 15 min, 20 min, 0.5 h, 1 h, 2 h, 3 h, 6 h, 10 h, 15 h, and 24 h. Each diluted sample was normalized to time point 0 and data from all four samples were pooled.

[0071] Surface plasmon resonance (SPR) was applied to measure the IC of IRDye800-AE344 on uPAR·uPA interactions in solution using a Biacore 3000 instrument essentially as described. 50 Briefly, pro-uPA, the natural ligand of uPAR, was measured. S356A It was recombinantly produced by mutating the active site S356A such that it has no enzymatic activity (thus substituting the active site Ser with an inactive Ala at S356A) and immobilized on a CM5 sensor chip providing very high surface densities of pro-uPA (>5000 RU - 0.1 pmol pro-uPA / mm 2 This is because when only low concentrations of uPAR were tested (here, 0.06 nM to 2 nM), the observed association rate (v obs) is directly proportional to the concentration of binding-active uPAR in solution, resulting in a largely mass-transport limited reaction. The analysis was performed by measuring the νobs of a fixed uPAR concentration (2 nM) incubated with a 3-fold dilution series of IRDye800-AE344 (ranging from 0.076 nM to 1.5 μM) at 20 °C for 300 s at a flow rate of 50 μL / min. To verify the biological integrity of the sensor chip, a standard curve was measured in parallel, including one replicate concentration point at the end (2-fold dilutions of uPAR covering 0.06 nM to 2 nM). The running buffer contained 10 mM HEPES, 150 mM NaCl, 3 mM EDTA and 0.05% (v / v) surfactant P20, pH 7.4. The sensor chip was regenerated with two injections of 0.1 M acetic acid, 0.5 M NaCl. The parent nonamer peptide antagonist AE105 (Asp-Cha-Phe-D-Ser-D-Arg-Tyr-Leu-Trp-Ser-OH) was analyzed in parallel as a positive control, inhibiting the closed form of uPAR. H47C-N259C was used as a negative control since its uPA binding cavity cannot accommodate AE105.

[0072] Cell lines and culture. U-87 MG-luc2 cells (Caliper, Hopkinton, MA, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM) + GlutaMAX supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C in humidified 5% CO2 air. Cells were passaged or harvested when they reached 80–90% confluency.

[0073] Animal models All experimental procedures in animals were performed in accordance with approval by The Animal Experiments Inspectorate, Denmark. 7-10 week old female nude mice (strain: Rj:NMRI-Foxn1nu / nu, JANVIER LABS, France) were orthotopically implanted with U-87 MG-luc2 cells. Before any surgical procedure, animals were anesthetized with a 1:1:2 ratio of Hypnorm (0.315mg / ml fentanyl, 10mg / ml fluanisone) + midazolam (5mg / ml) + sterile water by subcutaneous injection of 0.01ml / g body weight of the solution.

[0074] Orthotopic GBM tumor models were established by inoculating 500.000 cells in 10 μL of ice-cold PBS in the right hemisphere (1.5 mm lateral and 0.5 mm posterior to bregma at a depth of 2 mm) using a stereotaxic frame (KOPFINSTRUMENTS, Tujunga, CA, USA) with an automated microinjection pump UMP3 (WPI, Sarasota, FL, USA). Cells were injected over 5 min and the syringe was kept in place for an additional 3 min before being removed. Tumor growth was then monitored by MRI using a BioSpec7T (Bruker, Billerica, MA, USA) with axial and coronal T2-weighted sequences. Tumors with sizes ranging from 2 to 17 mm were observed. 3 Once this was reached, the animals were included in the fluorescent imaging protocol.

[0075] Fluorescence imaging All image acquisition was performed with a fluorescence beam system using (Fluosoft version: 2.2.1) (Fluoptics, Grenoble, France). To characterize the in vivo biodistribution and tumor imaging properties, IRDye800-AE344 was administered by tail vein injection to all GBM-bearing mice (n=35) at four different doses: 1 nmol, 3 nmol, 6 nmol and 12 nmol. Two mice for each time point were sacrificed, brains were removed and tumors were cross-sectioned for imaging. Preliminary studies revealed that higher doses resulted in slower background clearance and extended time windows. Therefore, image acquisition was performed at the following time points after injection: 1nmol: 0.5 hours, 1 hour and 2 hours 3nmol: 1 hour, 2 hours, 3 hours and 5 hours 6nmol: 1 hour, 3 hours, 6 hours and 12 hours 12nmol: 1 hour, 3 hours, 5 hours, 10 hours, 15 hours and 24 hours Target specificity for uPAR was assessed by two different methods: competitive blocking with the uPAR-targeting peptide AE120 ((DChaFsrYLWSG)2-βAK), which has a peptide length similar to the active peptide, and IRDye800 conjugated to the scrambled peptide AE354 (IRDye800CW-Glu-Glu-NH-CH2-CH2-O-CH2-CH2-O-CH2-CO-NH-CH2-CH2-O-CH2-CH2-O-CH2-CO-Asp-Cha-Glu-(D)Ser-(D)Arg-Tyr-Leu-Glu-Ser-OH). Competitive blocking doses of 1.4–2.8 mg of AE120 were injected intraperitoneally 15–30 min prior to intravenous injection of 3 nmol of IRDye800CW-AE344 and imaged at 1 h (n=5). Scrambled peptide was administered at 3 nmol and animals were imaged 1 hour later (n=4).

[0076] Biodistribution was evaluated in animals (n=2) administered 3 nmol IRDye800-AE344 and euthanized 1 h later for organ dissection and imaging (exposure time: 333 ms). Due to renal excretion, the fluorescent signal in the kidney was out of scale compared to all other organs. Therefore, images were acquired with exposure times as low as 40 ms and the signal intensity was then extrapolated to be comparable to other organs. The skin was imaged in sections (1.25 g) and the biodistribution was extrapolated to the total weight of the skin (4.9 g).

[0077] Image Processing and Analysis Images were analyzed and processed with ImageJ1.52a (NIH, USA). Signal measurements were performed on raw images generated by the Fluoptics system. Tumor signal was measured as the mean fluorescence intensity of the entire tumor, and background signal was measured as the average of a representative tumor-free area in the contralateral hemisphere. Images shown are contrast enhanced in ImageJ using contrast enhancement (saturated pixels: 0.3%).

[0078] Pathological evaluation Pathological evaluation was used to evaluate the colocalization of the fluorescent signal with cancer cells (sens+spec). Sectioned brain specimens from fluorescent imaging were paraffin embedded for H&E and IHC staining or cryostat sectioned for fluorescent microscopy. Paraffin embedding was performed by suspension in ethanol followed by fixation in 4% formalin for 24 h and subsequent paraffin embedding. Embedded tissues were cut axially into xx μm thick sections and stained. IHC staining was performed with an in-house antibody, poly-rabbit-anti-human-uPAR, produced by Finsen Laboratory, Rigshospitalet (Copenhagen, Denmark), and H&E staining was performed by common standard procedures. Stained slides were imaged with a ZEISS Axio Scan.Z1 slide scanner (Carl Zeiss, Oberkochen, Germany).

[0079] Cryostat sectioning was performed by fixing specimens in a Tissue-Tek OCT on dry ice. Fixed tissues were sliced ​​axially and mounted onto slides for immediate fluorescent imaging.

[0080] Liver and kidney: Tissues were formalin fixed and paraffin embedded. Sections 2-4 μm thick were cut and routine staining panels were applied including H&E, modified Sirius, PAS and Masson trichrome for both kidney and liver, additional PAS with silver for kidney, and PAS with diastase, iron, reticulin artisan and oxidized orcein for liver. Liver was stained immunohistochemically and immunohistochemical evaluation was performed on 3 μm thick sections using CK7 antibody, GA619 (clone OV-TL12 / 30) from Dako / Agilent according to the manufacturer's instructions. Staining was performed on Agilent Omnis using EnVisionFlex+ detection kit (GV800). Primary antibodies were diluted with Antibody Diluent (Dako DM830) and incubated for 20 min. Sections were counterstained with hematoxylin.

[0081] Materials and procedures for peptide synthesis material IRDye800-Glu-Glu-O2Oc-O2Oc-Asp-Cha-Phe-D-ser-D-arg-Tyr-Leu-Trp-Ser-OH. All other materials were obtained from commercial suppliers. Fmoc Ser(t-Bu) TentaGel S PHB 0.25 mmol / g was from Rapp Polymere GmbH. All amino acids were FmocNα-amino protected and carried side chain protecting groups: tert-butyl (Ser, Asp, Glu and Tyr), tert-butyloxycarbonyl (Boc, for Trp), 2,2,4,6,7 pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf, for Arg). Fmoc-O2Oc-OH Fmoc-[2-(2-aminoethoxy)ethoxy]acetic acid N,N-dimethylformamide (DMF), N-methylpyrrolidone (NMP), N-[(1H-benzotriazol-1-yl)(dimethylamino)methylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HBTU), 1-hydroxy-7-azabenzotriazole (HOAt), trifluoroacetic acid (TFA), piperidine, and N,N-diisopropylethylamine (DIPEA) were obtained from Iris Biotech. The reagents were from Agrochemicals GmbH, whereas methanol, acetonitrile, formic acid, triethylsilane (TES), dichloromethane (DCM), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate, N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU) were from Sigma-Aldrich. IRDye® 800CW carboxylate was from LI-COR.

[0082] Peptide synthesis Peptides were prepared by Fmoc solid phase peptide synthesis on an automated peptide synthesizer: Biotage® Syro Wave. Synthesis was carried out on FmocSer(t-Bu)TentaGelSPHB 0.25mmol / g resin using a 0.1mmol scale.

[0083] N α Fmoc deprotection was performed in two steps at room temperature (RT) by treating the resin with piperidine / DMF (2:3) solution for 3 min followed by piperidine / DMF (1:4) solution for 15 min. The resin was then washed with NMP (3 times), DCM (1 time) and then NMP (2 times). All amino acid couplings used 4 equivalents of amino acid and O2Oc spacer, 4 equivalents of HOAt, 3.9 equivalents of HBTU and 7.4 equivalents of DIEA in NMP. Coupling time was 60 min at room temperature. All couplings were repeated to ensure maximum incorporation and the resin was washed with NMP after the second coupling (4 times).

[0084] Once all amino acids and O2Oc spacers were attached and the final Fmoc group was removed, a test cleavage was performed, which showed that the purity calculated from the LC-MS chromatogram was greater than 80%. To attach the fluorophore to the synthesized peptide, 5 mg of IRDye® 800CW carboxylate was dissolved in 1 ml of DMF. To this, 2 mg of HATU, 1 mg of HOAT and 1.7 μl of DIEA were added. The solution was shaken for 5 minutes and then transferred to 100 mg of resin containing the synthesized peptide and reacted in the dark for 12 hours. After the final reaction, the resin was washed with DMF (5 times) and DCM (6 times). The peptide was then cleaved from the resin with 95% TFA; 5% water with a reaction time of 2 hours. The TFA was removed with a stream of nitrogen. The peptide was then precipitated in cold diethyl ether.

[0085] purification The crude peptides were purified by a three-step process on RP-HPLC (Dionex Ultimate 3000 system equipped with a fraction collector). First, the peptides were purified on a preparative C18 column (Phenomenex Gemini, 110 Å 5 μm C18 particles, 21 × 100 mm) using the following solvent system: solvent A, water containing 0.1% TFA; solvent B, acetonitrile containing 0.1% TFA. Gradient elution (0-5 min: 5%; 5%-60% 5-32 min) was applied at a flow rate of 15 mL / min. Fractions containing the fluorescent peptides were lyophilized. They were purified in step 2 using a preparative C4 column (Phenomenex jupiter, 300 Å 5 μm C18 particles, 21 × 100 mm) using the following conditions (solvent system: solvent A, water containing 0.1% TFA; solvent B, methanol containing 0.1% TFA). Gradient elution (0-5 min: 5%; 5%-60% 5-32 min) was applied at a flow rate of 15 mL / min. The fractions containing the fluorescent peptide were lyophilized. The final step of purification was then performed on a preparative C18 column (Phenomenex Gemini, 110 Å 5 μm C18 particles, 21 × 100 mm) using the following solvent systems: Solvent A, water containing 0.1% TFA; Solvent B, acetonitrile containing 0.1% TFA. Gradient elution (0-5 min: 5%-30; 30%-40% 5-40 min) was applied at a flow rate of 15 mL / min.

[0086] analysis Peptide purity was confirmed using two different analytical methods implemented on an RSLC Dionex Ultimate 3000 (Thermo) instrument coupled to a QTOF Impact HD for UHPLC-MS. In the first method, an Aeris 3.6 μm wide-pore C4 column (50 × 2.1 mm, Phenomenex) with a flow rate of 0.5 mL / min was used with the following solvent system: solvent A, water containing 0.1% formic acid; solvent B, methanol containing 0.1% formic acid. The column was eluted using a linear gradient from 5% to 75% solvent B.

[0087] The second method involved a kinetex 2.6 μm EVO 100 Å C18 column (50×2.1 mm, Phenomenex) with a flow rate of 0.5 mL / min. The following solvent system was used: Solvent A, water containing 0.1% formic acid; Solvent B, acetonitrile containing 0.1% formic acid. The column was eluted with a linear gradient from 5% to 100% solvent B. The synthesis yielded 2 mg of 98% pure peptide. Chemical formula: C 129 H 173 N 18 O 41 S4. Estimated mass 2758.0888; Measured value: [M+2H] 2+ 1380.0523;[M+3H] 3+ 920.3723;[M+4H] 4+ 690.5289

[0088] Consideration The key features of an optimal fluorescent probe well suited for surgical guidance are 1) high sensitivity and specificity, 2) high TBR achieved within a few hours, 3) low dose required to obtain a high fluorescent signal, and 4) a favorable safety profile. In this study, we successfully synthesized a new peptide-based fluorescent probe that effectively visualizes GBM in vivo with a TBR above 4.5 between 1 and 12 hours after injection of a 6 nmol dose. This allows for flexible use and complies with standard workflows in surgical departments where the probe may be injected just before surgery, e.g., during surgical preparation or induction of anesthesia. The useful time window starts when surgery is initiated and persists throughout the entire long procedure. Thus, the use of small peptide-based probes seems particularly applicable for clinical intraoperative imaging. Thus, we have shown that fluorescence-guided resection of human orthotopic GBM xenografts can be performed in mice as early as 3 hours after administration of 6 nmol IRDye800CW-AE344.

[0089] In contrast, antibody-based probes, due to their large molecular size, circulate in the blood for a long time (several days), compromising high TBR at early time points due to high background signals persisting for several days. A sufficiently high TBR can be obtained by simply waiting a few days after injection. IRDye800CW-cetuximab, an antibody-based fluorescent probe with a reported half-life in the blood of about 24 hours, has been tested in humans with GBM and required injection 3 days before surgery (28,29). In our view, this may be impractical and does not fit into the established clinical workflow, requiring patients to visit the hospital for additional consultations several days before surgery. It is also not uncommon for surgery to be postponed or canceled at the last minute, in which case the antibody-based probe would have already been injected and would therefore be wasted. Injected antibodies generally carry the well-known risk of side effects, especially immune-related adverse events. Thus, the use of antibody-based probes for fluorescence-guided surgery seems to be very inconvenient from a clinical point of view limiting their applicability and may not be the most obvious approach. To reduce the size while maintaining the high binding affinity properties of antibodies and improving their pharmacokinetic profiles, various strategies have been pursued, resulting in a variety of smaller antibody fragments, such as nanobodies and affibodies, with high binding affinity and somewhat reduced circulation times.

[0090] The new probes according to the invention are expected to be well tolerated and safe in humans. This is based on the fact that the components have been used in humans before without safety issues. First, the binding moieties of the invention have been shown to be effective in treating multiple cancer types (14,34) (NCT03278275, NCT02755675, NCT03307460, NCT02960724, NCT02805608, NCT02964988, NCT02681640, NCT02965001), including an ongoing Phase II trial in GBM patients (NCT02945826). 68It has been previously tested as Ga-NOTA-AE105). In total, over 400 patients have been investigated to date, with no adverse events or toxicities observed, and no on-target or off-target toxicities, suggesting a favorable safety profile. Second, IRDye800CW is a novel fluorophore that has been tested to be safe in humans, although not as extensively as the traditional fluorophore ICG, which has been proven safe on a large scale. However, IRDye800CW has excellent optical and pharmacokinetic properties with increased brightness, less bleaching, and rapid renal clearance. Currently, at least 10 clinical trials are being conducted with IRDye800CW-labeled probes. Most of these studies have been with IRDye800CW-labeled antibodies, with only one study using a labeled small peptide. There have been no reports of severe adverse events, and the reported mild side effects are most likely similar to antibody reactions. Therefore, based on the safety profiles of the uPAR targeting peptide and IRDye800CW, one can reasonably assume that the safety profiles of the two compounds, separately and in combination, are also safe for human use. In support of this, our pathological evaluation of the kidney and liver showed no pathological findings indicating no toxicity in these organs, particularly the kidney where the probe accumulates and is eliminated. Furthermore, IRDye800CW has similar spectral properties to ICG, allowing compatibility with existing imaging devices designed for ICG, which is key to successful transfer and clinical implementation.

Claims

1. 1. A urokinase plasminogen activator receptor (uPAR) targeting peptide conjugate comprising: Fluorophores, A peptide that binds to uPAR, and comprising a linker group, The formula: 【Chemistry 1】 A urokinase plasminogen activator receptor (uPAR) targeting peptide conjugate comprising:

2. 10. The uPAR targeting peptide conjugate of claim 1 for use in the treatment of a disease.

3. 10. The uPAR targeting peptide conjugate of claim 1 for use in the diagnosis of a disease.

4. 10. The uPAR targeting peptide conjugate of claim 1 for use in optical or fluorescent imaging (FLI) of disease.

5. The uPAR targeting peptide conjugate for use according to any one of claims 2 to 4, wherein said disease is selected from the group consisting of cancer and inflammatory diseases.

6. The uPAR targeting peptide conjugate for use according to any one of claims 2 to 4, wherein the uPAR targeting peptide conjugate is administered to a subject at a dose of 0.1 to 1000 mg per person.

7. A pharmaceutical composition comprising the uPAR targeting peptide conjugate of claim 1 together with at least one pharma- ceutically acceptable carrier or excipient.

8. 8. A pharmaceutical composition according to claim 7 for use in the treatment of a disease.

9. A pharmaceutical composition according to claim 7 for use in the detection and / or quantification of a disease.

10. A pharmaceutical composition according to claim 7 for use in the diagnosis of a disease.

11. 8. The pharmaceutical composition according to claim 7 for use in optical or fluorescent imaging (FLI) of a disease.

12. The pharmaceutical composition for use according to any one of claims 8 to 11, wherein the disease is selected from the group consisting of cancer and inflammatory diseases.

13. 13. The pharmaceutical composition for use according to claim 12, wherein the cancer is selected from the group consisting of glioma, glioblastoma or other brain cancer, pancreatic cancer, oropharyngeal cancer, head and neck cancer, breast cancer, lung cancer, colorectal cancer, esophageal cancer, gastric cancer, liver cancer, neuroendocrine tumors, neuroendocrine carcinomas, and prostate cancer.

14. 14. The pharmaceutical composition for use according to claim 12 or 13, wherein the cancer is selected from the group consisting of glioma, glioblastoma, pancreatic cancer, head and neck cancer, colorectal cancer, lung cancer and breast cancer.

15. The pharmaceutical composition for use according to any one of claims 12 to 14, wherein the cancer is glioma, glioblastoma or breast cancer.

16. 13. The pharmaceutical composition for use according to claim 12, wherein the inflammatory disease is selected from the group consisting of arthritis and atherosclerosis.

17. 9. A pharmaceutical composition according to claim 8 for use in delineating cancer tumours or metastases.

18. 9. The pharmaceutical composition of claim 8 for use in fluorescence guided tumor resection or metastasectomy.

19. A pharmaceutical composition for use according to any of claims 8 to 18, which is administered intravenously, topically or locally.

20. 20. The pharmaceutical composition for use according to any one of claims 8 to 19, wherein the concentration of the uPAR targeting peptide conjugate is in the range of 0.1 to 1000 mg per dosage unit, typically 0.001 to 1000 mg per dosage unit, 0.01 to 1000 mg per dosage unit, 0.1 to 1000 mg per dosage unit, 0.0001 to 500 mg per dosage unit, 0.001 to 500 mg per dosage unit, 0.01 to 500 mg per dosage unit, 0.1 to 500 mg per dosage unit, 0.0001 to 100 mg per dosage unit, 0.001 to 100 mg per dosage unit, 0.01 to 100 mg per dosage unit, or 0.1 to 100 mg per dosage unit.

21. 1. A kit of parts for preparing a unit dose of a uPAR targeting peptide conjugate formulation, comprising: A unit dose of the pharmaceutical composition according to claim 7. Optionally, a unit dose of at least one pharmacologically active agent; optionally, a unit dose of an adjuvant; Optionally, at least one pharma- ceutically acceptable carrier or excipient in the unit dose; means for separating the unit doses from one another prior to administration; and A means for administering a unit dose, A kit comprising:

22. 22. The kit of parts according to claim 21, wherein the unit dosage of the pharmaceutical composition according to claim 21 is in the range of 0.1 to 1000 mg, typically 0.001 to 1000 mg, 0.01 to 1000 mg, 0.1 to 1000 mg, 0.0001 to 500 mg, 0.001 to 500 mg, 0.01 to 500 mg, 0.1 to 500 mg, 0.0001 to 100 mg, 0.001 to 100 mg, 0.01 to 100 mg or 0.1 to 100 mg.

23. 23. The kit of parts according to claim 21 or 22, wherein said unit dose has a total volume in the range of 0.1 to 10.0 mL, preferably in the range of 0.1 to 5.0 mL, preferably in the range of 0.5 to 5.0 mL, preferably in the range of 0.5 to 1.0 mL.

Citation Information

Patent Citations

  • uPAR (urokinase-type plasminogen activator receptor) targeted peptides, probe and living molecular imaging method

    CN107652358A

  • upar targeting contrast agent

    JP2008514588A

  • Upar targeting peptide for use in peroperative optical imaging of invasive cancer

    WO2016041558A1